List of Excipients in Branded Drug NALTREXONE HYDROCHLORIDE

Generic Drugs Containing NALTREXONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
SpecGx LLC	naltrexone hydrochloride	0406-1170	CELLULOSE, MICROCRYSTALLINE
SpecGx LLC	naltrexone hydrochloride	0406-1170	CROSPOVIDONE
SpecGx LLC	naltrexone hydrochloride	0406-1170	FERRIC OXIDE RED
SpecGx LLC	naltrexone hydrochloride	0406-1170	FERRIC OXIDE YELLOW
SpecGx LLC	naltrexone hydrochloride	0406-1170	HYPROMELLOSE
SpecGx LLC	naltrexone hydrochloride	0406-1170	LACTOSE MONOHYDRATE
SpecGx LLC	naltrexone hydrochloride	0406-1170	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in NALTREXONE HYDROCHLORIDE?

# Of NDCs	Excipient
30	ANHYDROUS LACTOSE
55	CELLULOSE, MICROCRYSTALLINE
1	CI 77891
30	CROSCARMELLOSE SODIUM
25	CROSPOVIDONE
27	FERRIC OXIDE RED
57	FERRIC OXIDE YELLOW

Naltrexone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Naltrexone hydrochloride is an off-patent opioid antagonist with established use in alcohol use disorder and opioid use disorder. The strongest commercial opportunities are not in the active ingredient itself, but in differentiated oral delivery, long-acting injectable systems, adherence products, combination therapies, and excipient-enabled manufacturing platforms.

The market separates into four product categories:

Product category	Representative product	Commercial position	Main opportunity
Immediate-release oral tablets	Generic naltrexone hydrochloride	Highly commoditized	Low-cost manufacturing, lower-dose products, adherence packaging
Oral capsules or specialty tablets	Generic and 505(b)(2) candidates	Limited differentiation	Taste masking, modified release, pediatric and geriatric use
Extended-release injectable suspension	Vivitrol, Alkermes	Branded, clinically differentiated	Depot technology, lower-cost alternatives, administration improvements
Combination products	Naltrexone/bupropion, investigational combinations	Obesity and addiction markets	Fixed-dose delivery, tolerability, abuse-deterrent positioning

Naltrexone hydrochloride has favorable chemical economics, no biosimilar pathway risk, and broad formulation flexibility. Its principal constraints are poor patient adherence with daily oral dosing, opioid-precipitated withdrawal, hepatic safety considerations, and the difficulty of matching the clinical performance of a long-acting injectable product.

What is naltrexone hydrochloride used for?

Naltrexone hydrochloride is an opioid receptor antagonist used for alcohol dependence and opioid dependence after patients have completed opioid detoxification. The oral product is commonly dosed at 50 mg once daily, although clinical regimens vary. It has no opioid agonist activity and does not produce opioid euphoria when used as directed.[1]

The principal approved product categories are:

• Oral naltrexone hydrochloride tablets for alcohol dependence and opioid dependence.
• Extended-release injectable naltrexone for alcohol dependence and prevention of opioid relapse.
• Naltrexone/bupropion extended-release tablets for chronic weight management, where naltrexone is combined with bupropion in a separate branded product.[2]

Naltrexone is not a biologic. Biosimilar competition is therefore irrelevant. Competitive entry occurs through abbreviated new drug applications, 505(b)(2) applications, pharmaceutical equivalence, therapeutic equivalence, or differentiated formulation claims.

What excipients are used in naltrexone hydrochloride tablets?

Commercial oral naltrexone tablets typically use conventional excipients such as lactose or other fillers, microcrystalline cellulose, crospovidone or sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, and film-coating materials. The exact composition varies by manufacturer and dosage form.[3]

A typical immediate-release formulation requires:

Formulation function	Candidate excipients	Commercial purpose
Dilution and dose uniformity	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Supports 25 mg to 50 mg tablets and content uniformity
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Provides rapid release
Lubrication	Magnesium stearate, sodium stearyl fumarate	Improves tableting and ejection
Flow improvement	Colloidal silicon dioxide	Reduces segregation and improves feeding
Taste masking	Film coatings, ion-exchange resins, polymeric coatings	Supports orally disintegrating or chewable products
Moisture control	Hypromellose, polyvinyl alcohol, protective packaging	Improves stability
Color and identification	Iron oxides, titanium dioxide where permitted, approved lake colors	Reduces dispensing errors and supports product recognition

The basic tablet is difficult to differentiate because the active ingredient is inexpensive, the dose is modest, and conventional excipients are widely available. A new product needs a clinically relevant advantage, a manufacturing-cost advantage, or a regulatory pathway that avoids direct substitution with standard generic tablets.

Which excipient strategies can differentiate naltrexone hydrochloride?

Taste masking and orally disintegrating tablets

Taste masking is a practical opportunity because naltrexone hydrochloride can be unpleasant when dissolved in the mouth. An orally disintegrating tablet could improve administration for patients with swallowing difficulty, patients in supervised treatment settings, and populations requiring rapid administration.

Potential technologies include:

• Polymer film coating of drug particles.
• Ion-exchange resin complexes.
• Lipid or wax coating.
• Spray-dried polymer matrices.
• Mannitol-based orally disintegrating tablets.
• Multiparticulate systems filled into capsules or compressed into tablets.

The regulatory value depends on whether the product offers evidence of improved acceptability, reduced administration time, or better adherence. Taste masking alone may support formulation differentiation but may not justify a premium without a meaningful patient benefit.

Low-dose tablets and dose flexibility

The standard 50 mg dose creates an opportunity for 12.5 mg and 25 mg strengths. Lower strengths may support titration, re-initiation after treatment interruption, pediatric development where appropriate, or combination products.

Excipient strategy should prioritize:

• High drug-load uniformity at low dose.
• Segregation control during blending.
• Scored tablets or mini-tablets.
• Direct compression when powder flow is adequate.
• Low-shear granulation to reduce processing cost.
• Packaging that permits flexible dose escalation.

Low-dose products may be more suitable for a 505(b)(2) strategy than a conventional ANDA if the sponsor seeks a distinct dosing regimen or clinical-use profile.

Modified-release oral formulations

Modified-release naltrexone could target adherence by reducing daily dosing frequency. Candidate approaches include hydrophilic matrix tablets, osmotic systems, multiparticulate capsules, and gastroretentive delivery.

The commercial case is challenging. Naltrexone has a relatively short plasma half-life, while its active metabolite, 6-beta-naltrexol, contributes to pharmacology. A modified-release product would need to demonstrate suitable exposure, efficacy, safety, and resistance to dose dumping.

The strongest formulation claims would cover:

• Polymer composition and release profile.
• Particle size and granulation parameters.
• Food-effect control.
• Reduced peak-to-trough variation.
• Once-weekly or less frequent oral dosing.
• Improved tolerability or treatment persistence.

A modified-release product may obtain protection through formulation patents, but FDA approval would require clinical bridging or other evidence sufficient to establish the new dosage form.

Abuse-deterrent and tamper-resistant formulations

Naltrexone does not produce opioid euphoria, so classic abuse-deterrent positioning is less compelling than for opioid analgesics. The commercial rationale is different: preventing manipulation of a product in treatment settings, reducing accidental dosing errors, and creating a formulation resistant to crushing or extraction.

Potential approaches include hard matrices, polymer networks, and multiparticulate systems. These technologies are more likely to support institutional or specialty-care positioning than broad retail demand.

Fixed-dose combination products

Naltrexone is already used in combination with bupropion for chronic weight management. The combination has commercial relevance in obesity, although it competes with GLP-1 receptor agonists and other anti-obesity medicines.

Excipient and formulation opportunities include:

• Separate release profiles for naltrexone and bupropion.
• Reduced early naltrexone exposure to improve tolerability.
• Smaller tablets or once-daily dosing.
• Gastrointestinal-release control.
• Packaging that supports dose escalation.
• Stabilization of both active ingredients in a single dosage form.

A combination product requires careful management of dose titration, nausea, blood-pressure effects, seizure risk, and opioid contraindications. Excipient changes that alter either component’s exposure may create clinical and regulatory complexity.[2]

What excipients are used in long-acting injectable naltrexone?

Vivitrol is an extended-release injectable suspension containing naltrexone microspheres. The microspheres use a biodegradable polymer delivery system, generally based on poly(lactide-co-glycolide), or PLG. The product also contains injectable suspension excipients and is supplied with a diluent and administration components.[4]

The long-acting injectable platform creates a much higher technical barrier than oral tablets. Key formulation attributes include:

Attribute	Technical requirement
Polymer composition	Controls degradation and drug release
Microsphere size	Influences syringeability, injection-site behavior, and release
Porosity	Controls water ingress and drug diffusion
Residual solvent	Must comply with ICH and FDA expectations
Suspension stability	Prevents aggregation and dose nonuniformity
Reconstitution time	Affects clinical workflow
Needle compatibility	Supports reliable intramuscular administration
Release duration	Must maintain clinically useful exposure
Sterility and endotoxin control	Required for parenteral products

A lower-cost long-acting injectable is the most commercially attractive formulation opportunity, but it is also the most difficult. The sponsor would need to address polymer selection, microsphere manufacturing, scale-up, suspension behavior, injection-site tolerability, and clinical equivalence.

What patents protect naltrexone hydrochloride products?

The original naltrexone compound and standard oral tablet technology are long off-patent. Generic oral naltrexone hydrochloride products have been marketed for many years, and no meaningful composition-of-matter exclusivity remains for the active ingredient.[3]

The relevant intellectual-property categories are:

1. Long-acting injectable microsphere formulations.
2. Polymer composition and degradation profiles.
3. Particle-size distributions and manufacturing processes.
4. Reconstitution systems and administration devices.
5. Combination products containing naltrexone.
6. Modified-release oral formulations.
7. Method-of-use claims for specific patient populations or dosing regimens.

Vivitrol has historically been protected by patents directed to extended-release naltrexone microspheres and related delivery technology. The commercial value of those patents depends on the specific patent family, claim scope, terminal disclaimers, Orange Book listing status, and judicial treatment. The active ingredient itself does not create a barrier to generic entry.

How strong is the patent estate for naltrexone?

The patent estate is weak for conventional oral naltrexone and materially stronger for long-acting injectable delivery.

Product type	Composition-of-matter protection	Formulation protection	Manufacturing barrier	Overall position
50 mg immediate-release tablet	Expired	Limited	Low	Weak
Taste-masked tablet	Expired	Potentially moderate	Low to moderate	Moderate if clinically differentiated
Modified-release tablet	Expired	Potentially strong	Moderate	Moderate
Naltrexone/bupropion combination	Expired for naltrexone; combination claims may vary	Moderate to strong	Moderate	Product-specific
PLG microsphere injection	Expired for naltrexone	Stronger	High	Strongest opportunity for defensible IP

Formulation patents are most valuable when they claim measurable performance, such as sustained release, particle size, release kinetics, or injection behavior. Broad claims based only on routine excipient substitution are more vulnerable to invalidity and design-around strategies.

What is the FDA and Orange Book status of naltrexone products?

FDA-approved oral naltrexone hydrochloride products are generally available as generic prescription drugs. Their regulatory pathway is typically an ANDA demonstrating pharmaceutical equivalence and bioequivalence to a listed reference product.[5]

The Orange Book framework is more important for branded combination products and extended-release injectable products than for standard oral naltrexone tablets. Sponsors assessing a launch should review:

• Reference listed drug status.
• Active ingredient and dosage-form designation.
• Orange Book patent listings.
• Pediatric exclusivity.
• New chemical entity exclusivity, where applicable.
• Paragraph IV certifications.
• Any 30-month stay triggered by a patent litigation action.
• Product-specific FDA guidance and bioequivalence recommendations.

A conventional generic tablet has limited ability to generate a Paragraph IV opportunity because the core active ingredient and basic dosage form are old. The more attractive Paragraph IV targets are branded modified-release products, combination products, and long-acting injectable formulations with listed formulation patents.

When does naltrexone lose exclusivity?

The active ingredient has already lost exclusivity. Conventional oral naltrexone hydrochloride is a mature generic market.

The exclusivity analysis is product-specific:

Exclusivity source	Oral naltrexone tablet	Long-acting injectable	Naltrexone/bupropion
Active-ingredient patent	Expired	Expired	Expired for naltrexone
Standard generic entry	Established	More difficult	Product-specific
Formulation patents	Limited	Central to strategy	Important
Regulatory exclusivity	Generally expired	Product-specific	Product-specific
Biosimilar risk	None	None	None
Paragraph IV relevance	Limited	Potentially significant	Potentially significant

No single expiration date determines the entire naltrexone market. A generic tablet can launch despite the absence of patent barriers affecting a separate injectable product. Conversely, a long-acting injectable can remain commercially protected through formulation and manufacturing patents after the active ingredient is fully generic.

Which companies compete in naltrexone hydrochloride?

The competitive landscape includes generic manufacturers, branded specialty pharmaceutical companies, and developers of addiction and obesity products.

Generic oral manufacturers

Generic oral naltrexone is supplied by multiple U.S. and international manufacturers. Competition is based on:

• API sourcing.
• Tablet yield and manufacturing cost.
• FDA compliance history.
• Supply reliability.
• Wholesaler and pharmacy contracts.
• Ability to maintain multiple strengths.
• Packaging and serialization efficiency.

Because the product is inexpensive and substitutable, margin compression is likely unless a manufacturer has a low-cost supply chain or a differentiated dosage form.

Alkermes and Vivitrol

Alkermes owns the commercial position in extended-release injectable naltrexone through Vivitrol. The product is used in opioid dependence and alcohol dependence, with administration every four weeks.[4]

Vivitrol’s commercial advantage is adherence control. A clinic or healthcare professional administers the dose, reducing the risk that a patient will stop daily treatment. Its disadvantages include injection-site reactions, injection logistics, cost, need for opioid abstinence before treatment, and the inability to rapidly remove the drug once administered.

Obesity competitors

Naltrexone/bupropion competes against GLP-1 receptor agonists, sympathomimetic products, and other obesity therapies. The commercial position of naltrexone in obesity is constrained by:

• Lower efficacy than leading incretin therapies.
• Gastrointestinal adverse effects.
• Titration requirements.
• Opioid contraindication.
• Cardiovascular and seizure-related prescribing considerations.

An excipient strategy can improve usability, but it is unlikely to eliminate the product’s pharmacologic limitations.

What commercial opportunities exist for naltrexone excipients?

Opportunity 1: Low-cost, high-quality generic supply

The most immediate opportunity is operational rather than inventive. A manufacturer can compete through:

• Direct compression.
• Continuous manufacturing.
• High-yield granulation.
• Reduced coating weight.
• Automated visual inspection.
• Smaller, moisture-resistant packaging.
• Dual sourcing of API and excipients.

Excipients with strong global supply and compendial support reduce regulatory and supply risk. Novel excipients may create unnecessary review complexity for a low-value generic product.

Opportunity 2: Orally disintegrating or chewable naltrexone

An ODT or chewable product could target supervised treatment programs, patients with dysphagia, and specialty pharmacies. The product would need effective taste masking and rapid disintegration without compromising dose uniformity.

A 505(b)(2) application may be appropriate if the product has a distinct dosage form, dosing regimen, or clinical-use profile that cannot be supported through a standard ANDA.

Opportunity 3: Pediatric and geriatric formulations

Liquid, mini-tablet, orally disintegrating, and low-dose formulations could support populations that cannot reliably swallow a 50 mg tablet. These products may also support controlled titration.

The commercial market is smaller than the adult generic market, but pricing can be better if the product improves administration and reduces compounding requirements.

Opportunity 4: Long-acting injectable competition

A follow-on injectable product could target clinics and public-sector purchasers seeking lower treatment costs. The product would face high development costs but could address a substantial commercial gap between inexpensive oral tablets and premium branded depot therapy.

The best development strategy would focus on:

• Reproducible microsphere manufacturing.
• Comparable release kinetics.
• Lower injection volume.
• Reduced injection-site reactions.
• Easier reconstitution.
• More efficient cold-chain and distribution requirements.

Opportunity 5: Drug-device integration

A prefilled or simplified administration system could reduce preparation errors and clinic labor. Potential developments include dual-chamber syringes, improved needle systems, and reconstitution devices.

Device claims may provide supplementary protection, but they are unlikely to block a competing injectable unless the device is required for the product’s performance or safety.

Opportunity 6: Treatment-program packaging

Naltrexone is used in structured addiction-treatment programs. Unit-dose packaging, adherence calendars, multilingual labeling, and starter kits may improve implementation without changing the drug formulation.

These products can create commercial value through institutional contracts, even when the tablet itself is interchangeable.

What manufacturing and IP barriers affect naltrexone products?

For oral tablets, the main barriers are regulatory compliance and cost control rather than proprietary technology. A manufacturer must manage:

• API impurity profile.
• Nitrosamine and elemental impurity assessment where applicable.
• Blend uniformity.
• Tablet hardness and friability.
• Dissolution reproducibility.
• Moisture sensitivity.
• Stability across distribution conditions.

For injectable microspheres, the barriers are substantially higher:

• Emulsion or solvent-evaporation process control.
• Microsphere morphology.
• Residual solvent removal.
• Aseptic processing.
• Sterile filtration limitations.
• Suspension homogeneity.
• Release testing over an extended period.
• Scale-up without altering release kinetics.

The manufacturing process itself may provide meaningful know-how even where patent protection is limited. Trade secrets involving polymer grade, solvent ratio, process temperature, mixing energy, and drying conditions can affect product performance.

What generic launch risks exist for naltrexone hydrochloride?

Oral tablet launch risks

Generic tablet launch risk is primarily commercial:

• Low reimbursement rates.
• Multiple approved suppliers.
• Pharmacy substitution.
• Price erosion.
• API supply interruptions.
• FDA inspection or warning-letter exposure.
• Limited differentiation.

A new entrant needs a structural cost advantage or a dependable supply proposition. A conventional tablet with no manufacturing advantage may struggle to earn attractive returns.

Injectable launch risks

The injectable opportunity has higher potential margins but also higher risks:

• Failure to demonstrate comparable exposure.
• Difficult-to-match microsphere release.
• Injection-site tolerability problems.
• Patent litigation.
• Product-specific FDA requirements.
• Complex manufacturing validation.
• Clinical-site and administration constraints.
• Payer resistance to a premium price.

A Paragraph IV challenge may accelerate market access if the relevant listed patents can be invalidated or designed around. The economics depend on litigation cost, settlement terms, launch timing, and the size of the injectable market.

How does naltrexone compare with competing addiction medicines?

Product	Active ingredient	Administration	Adherence profile	Key commercial advantage
Oral naltrexone	Naltrexone hydrochloride	Daily oral	Patient-dependent	Low cost
Vivitrol	Extended-release naltrexone	Monthly injection	Clinician-controlled	Reduced daily adherence burden
Buprenorphine products	Buprenorphine, often with naloxone	Daily, weekly, or monthly	Variable	Opioid agonist treatment with established retention
Methadone	Methadone	Daily supervised or take-home	Program-controlled	Strong efficacy in opioid use disorder
Acamprosate	Acamprosate calcium	Multiple daily doses	Difficult	Alcohol relapse prevention without opioid blockade

Naltrexone is differentiated by its lack of opioid agonism. That characteristic supports a non-opioid treatment option but creates a requirement for complete opioid abstinence before initiation. The commercial value of a formulation that improves adherence is therefore greater than the value of a minor tablet-performance improvement.

Key Takeaways

• Naltrexone hydrochloride is a mature, off-patent active ingredient with intense generic competition.
• Standard immediate-release tablets offer limited formulation and patent opportunities.
• Taste-masked ODTs, chewable tablets, low-dose strengths, and pediatric or geriatric dosage forms are the most practical oral opportunities.
• Long-acting injectable microspheres present the strongest technical and commercial opportunity, but also the highest development and litigation risk.
• PLG microsphere composition, particle size, release kinetics, manufacturing process, and administration technology are the primary defensible IP areas.
• Biosimilar risk does not apply because naltrexone is a small-molecule drug.
• Paragraph IV activity is more relevant to branded injectable and combination products than to standard oral naltrexone tablets.
• Excipient selection should favor compendial, globally available materials for generic tablets and performance-critical polymers for depot products.
• The best commercial strategy combines an adherence benefit with a regulatory pathway that avoids direct substitution with low-cost generic tablets.

FAQs

Can naltrexone hydrochloride be formulated as an oral liquid?

Yes. An oral liquid could use aqueous or cosolvent-based systems with pH control, preservatives, sweeteners, flavors, suspending agents, and taste-masking technology. The product would require stability, preservative-effectiveness, microbial, dosing-accuracy, and palatability data.

Is naltrexone hydrochloride suitable for transdermal delivery?

Transdermal delivery is technically possible but commercially uncertain. The required dose, skin permeability, patch wear time, and sustained-flux requirements would need to be established. A transdermal product would likely require a 505(b)(2) pathway and clinical evidence supporting the new route.

Can naltrexone excipients reduce opioid-precipitated withdrawal?

No excipient can remove the pharmacologic risk created by administering an opioid antagonist to a patient with residual opioid dependence. Formulation can improve dosing and adherence, but it cannot eliminate the need for opioid-free initiation.

What is the best excipient for a naltrexone orally disintegrating tablet?

Mannitol is commonly useful as a diluent and mouthfeel agent, while crospovidone or croscarmellose sodium can support rapid disintegration. A taste-masking polymer, resin complex, or coated-particle system may be needed because conventional sweeteners alone may not adequately control bitterness.

Does a new naltrexone formulation automatically receive new patent protection?

No. Patentability depends on novelty, non-obviousness, written description, enablement, and claim scope. Routine substitution of one conventional excipient for another is less likely to support strong patent protection than a formulation with unexpected release, stability, tolerability, or manufacturing performance.

References

1. U.S. Food and Drug Administration. (2023). Naltrexone hydrochloride tablets prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2023). Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Alkermes, Inc. (2024). Vivitrol prescribing information. FDA/DailyMed.

5. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA.